CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 56 enrolled
Drug / intervention
Atorvastatindrug
Likely dose
Atorvastatin 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00795912
NCT00795912Phase 4Completed
CompareCT.gov

A Study Of The Usage Of Statins In A Community Heart Failure Population: The Impact of HMG Co-Enzyme A Reductase Inhibitors on Heart Structural Parameters, Brain Naturetic Peptide, Markers of Inflammation and Fibrosis

St Vincent's University Hospital, Ireland·interventional·Posted Nov 21, 2008·Updated Nov 21, 2008

In Brief

A Phase 4 clinical trial evaluating Atorvastatin for Heart Failure. Completed, enrolled 56 participants across 1 site.

Detailed Summary

Inflammation and fibrosis may be important contributors to worsening heart failure. As well as lowering cholesterol, statins are also known to reduce inflammatory markers such as C-reactive protein which are elevated in severe heart failure. Therefore, this project will evaluate the benefit, if any, of statins on markers of heart structure and function, on inflammatory markers and markers of fibrosis in patients with normal cholesterol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesIreland
CollaboratorsUniversity of Dublin, Trinity College, University College Dublin, University College Cork

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 21, 2008
Enrollment StartMay 1, 2003
Primary CompletionNov 1, 2005
Study CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 17.6 years ago

Interventions

Atorvastatindrug

atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months